Re-Irradiation and Its Contribution to Good Prognosisin Recurrent Glioblastoma Patients
- Author:
Mi Sun KIM
1
;
Jaejoon LIM
;
Hyun Soo SHIN
;
Kyung Gi CHO
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Brain Tumor Research and Treatment 2020;8(1):29-35
- CountryRepublic of Korea
- Language:0
-
Abstract:
Background:: Radiation therapy, one of the strongest anti-cancer treatments, is already performed totreat primary glioblastoma; however, the effect of repeated radiation therapy for recurrent tumors has notbeen fully explored. The aim of this study was to determine the efficacy of re-irradiation in treating recurrentglioblastoma.
Methods:: The study included 36 patients with recurrent glioblastoma treated with repeated radiationtherapy between 2002 and 2016. Stereotactic radiosurgery (SRS) and hypo-fractionated stereotacticradiotherapy (HSRT) were performed in these patients.
Results:: Fourteen patients received SRS with a median dose of 25 Gy (range, 20-32 Gy) in1-5 fractions. Twenty-two patients received HSRT with a median dose of 40 Gy (range, 31.5-52 Gy) in6-20 fractions. There were six treatment-related grade 3 adverse events. Survival analysis showed thatre-irradiation significantly prolonged overall survival (OS) and progression-free survival (PFS). The medianOS and one-year OS rate after re-irradiation were 17.2 months and 60.4%, respectively. The medianPFS and 6-month PFS rate after re-irradiation were 4.4 months and 41.9%, respectively. Of the 36 patients,three survived without any progression in their condition.
Conclusion:: Re-irradiation for recurrent glioblastoma showed favorable outcomes. Radiation doseand fractionation should be carefully considered to minimize radiation necrosis.
